This article is published as part of Capsticks’ Medical Malpractice Forward View 2022.

Since early 2020, clinical trials have focused almost entirely on Covid-19 vaccines and treatments. This year is likely to see a resurgence of non-Covid trials which have been postponed or paused in the last two years, and new trials for Covid treatments and vaccines (e.g. those based on conventional vaccine technology and/or without the need for injection).

Increased activity in the sector will take place against a backdrop of the government’s Life Sciences Vision (LSV) and the Clinical Trials Consultation (CTC). The LSV is backed by a £200m investment programme. The CTC proposes various mechanisms to remove blockers to innovation and streamline the trials process (e.g. low intervention and cluster trials).

What this means for you: Both the LSV and CTC proposals present significant opportunities for those involved in clinical trials. Organisations involved in the sector are encouraged to respond to the CTC which closes on 14 March 2022. The increased number of trials will present increased risk, so you need to check the adequacy of your indemnity cover and the scope and robustness of your trials policies and procedures (in particular around participant eligibility criteria, consent and data security). Read our Insight on key practical considerations for those involved in clinical trials.

Medical Malpractice Forward View 2022 

This article is part of Capsticks’ Medical Malpractice Forward View 2022

Read the other articles featured in this publication below: 

Get in touch

Aiming to be the firm of choice for medical malpractice insurers and healthcare providers, we advise and support on all aspect of medical malpractice claims and inquests. 

To discuss how any of these issues may affect your organisation, please get in touch with Majid HassanSarah Bryant or Ed Mellor.